Deemed as the “drug that changed the breast cancer treatment landscape,” Herceptin has saved millions of women's lives ...

whether neoadjuvant chemotherapy was administered with trastuzumab alone or with an additional HER2-targeted agent, pathological nodal status at surgery, age cohorts, and race. However ...

In the UK, intravenous trastuzumab is used mainly as part of the combination with Perjeta and chemotherapy in breast cancer, and in metastatic gastric cancer. It will be in these indications where ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

In this small prospective cohort of 7 patients with resistant AOC, 3 achieved complete remission when adding trastuzumab to conventional chemotherapy, suggesting that trastuzumab combined with ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

It is also approved in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced, unresectable or metastatic ...